Αρχική World News FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle Cell... World News FDA Approves Acalabrutinib with Bendamustine and Rituximab for Previously Untreated Mantle Cell Lymphoma Από Ogkologos - 21 Φεβρουαρίου, 2025 1096 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the ECHO study Source ΠΑΡΟΜΟΙΑ ΑΡΘΡΑΠΕΡΙΣΣΟΤΕΡΑ ΑΠΟ ΤΟΝ ΔΗΜΙΟΥΡΓΟ Ahead of the Special European Council Meeting on 26-27 November, ESMO Calls on EU Governments to Continue Support for the Cancer Mission European Parliament backs key priorities advocated by ESMO for cancer research and innovation FDA approves giredestrant in combination with everolimus for ER-positive, HER2-negative, ESR1-mutated locally advanced or metastatic breast cancer MOST POPULAR Jennifer Garner Shared A Video Of Her Mammogram Appointment 21 Οκτωβρίου, 2019 EMA Recommends Granting a Marketing Authorisation for Elinzanetant 26 Σεπτεμβρίου, 2025 A New FDA Approval Furthers the Role of Genomics in Cancer... 8 Ιουλίου, 2020 Firefighter Advocates For Men’s Health While He Battles Breast Cancer In... 22 Σεπτεμβρίου, 2021 Φόρτωση περισσοτέρων HOT NEWS 2022 ASCO Annual Meeting: Advances in Treating Breast Cancer, Colorectal Cancer, Ewing... EMA Recommends Granting a Marketing Authorisation for Quizartinib EMA recommends granting a marketing authorisation for daraxonrasib Science Surgery: ‘Can cancers develop in the heart?’